TOX3 rs4784227: Understanding This Breast Cancer Risk Variant
The rs4784227 variant is a single-nucleotide polymorphism located in a non-coding regulatory region of the TOX3 gene. Research indicates this variant is statistically associated with an altered risk of developing breast cancer across various populations.
What each genotype means
Baseline breast cancer risk
This genotype represents the baseline risk profile for this specific genetic variant. Research indicates that individuals with this genotype do not carry the T allele associated with increased breast cancer susceptibility at this locus.
This is the most common genotype in many populations, though frequencies vary significantly by ancestry.
Slightly increased cancer risk
Carrying one copy of the T allele is associated with a statistically significant, modest increase in the risk of developing breast cancer. This variant is thought to influence the expression of the TOX3 gene, which may affect breast tissue regulation.
This heterozygous genotype is common, appearing in a significant portion of the population across both European and Asian ancestries.
Increased breast cancer risk
Individuals with two copies of the T allele show a higher statistical association with breast cancer risk compared to those with the C/C genotype. Because this association is based on population-level data, it does not predict an individual outcome; please discuss your overall health history and screening needs with your clinician.
This genotype is less common than the heterozygous form, with the T allele frequency typically ranging between 0.25 and 0.35 in European populations.
What is rs4784227 and Where is it Located?
The rs4784227 variant is a single-nucleotide polymorphism (SNP) situated at the 16q12.1 chromosomal locus. Unlike variants that change the protein-coding sequence of a gene, rs4784227 is located in a non-coding regulatory element. This means it does not alter the structure of the TOX3 protein itself, but rather influences how the gene is regulated. Scientific studies have identified this region as a critical site for chromatin interaction. Specifically, the presence of different alleles at this position can change the affinity of the chromatin for FOXA1, a transcription factor that plays a significant role in gene expression within breast tissue. By modulating this binding, the variant can influence the levels of TOX3 expression, which is thought to be a mechanism through which this genetic site contributes to breast cancer susceptibility.
The Role of the TOX3 Gene
TOX3, or TOX High Mobility Group Box Family Member 3, is a gene that encodes a protein involved in chromatin remodeling and transcriptional regulation. While the exact biological pathways are still being elucidated, TOX3 is known to be expressed in various tissues, including the brain and breast tissue. In the context of oncology, research has highlighted that TOX3 expression levels are often correlated with pathological features in breast cancer. Because the rs4784227 variant sits in a regulatory region that controls TOX3, it is hypothesized that the variant-driven changes in gene expression may affect cellular processes that, when dysregulated, contribute to the development or progression of breast tumors. Understanding this gene is a focus of ongoing research into the genetic architecture of breast cancer, particularly how non-coding variants contribute to complex disease risk.
Research and Evidence Strength
The association between rs4784227 and breast cancer has been observed in multiple genome-wide association studies (GWAS). Research has consistently shown a statistical link between this variant and breast cancer risk in both Asian and European American populations. For instance, pooled analyses have reported odds ratios indicating a modest increase in risk per allele. While the evidence for an association is strong in terms of statistical significance, the functional impact is considered a 'limited' health predisposition in many clinical contexts because genetic risk is multifactorial. It is important to note that having this variant does not mean an individual will develop cancer; rather, it is one of many genetic and environmental factors that contribute to overall risk. The scientific community continues to study how this variant interacts with other genetic markers and lifestyle factors to influence long-term health outcomes.
Population Frequency
The frequency of the rs4784227 variant varies across different ancestral groups. In European populations, the minor allele frequency is typically observed in the range of 0.25 to 0.35. Because allele frequencies are population-specific, the prevalence of the associated genotypes (homozygous for the major allele, heterozygous, or homozygous for the minor allele) will differ significantly depending on an individual's genetic ancestry. These frequency differences are a standard feature of human genetic diversity and are essential for researchers to consider when conducting cross-ancestry studies. Understanding these frequencies helps scientists determine the portability of genetic risk scores across different global populations, ensuring that findings are not limited to a single ancestral group.
What You Can and Cannot Do With This Information
Genetic information regarding variants like rs4784227 is intended for educational purposes and should not be used for self-diagnosis or medical decision-making. If you have concerns about your personal or family history of breast cancer, the most appropriate step is to consult with a healthcare professional or a certified genetic counselor. They can provide a comprehensive risk assessment that considers your entire genetic profile, family history, and lifestyle factors. You cannot use this information to predict a definitive health outcome, as breast cancer risk is complex and influenced by many variables beyond a single SNP. Always discuss any questions about genetic testing or health screenings with your doctor, who can provide guidance tailored to your specific medical needs and clinical history.
How common is this variant?
The minor allele frequency for rs4784227 is approximately 0.25-0.35 in European populations, with variations observed across other global ancestries.
Frequently asked questions
Does having the rs4784227 variant mean I will get breast cancer?
No, having this variant does not mean you will develop breast cancer. It is a statistical marker associated with a modest change in risk, which is only one of many factors that contribute to an individual's overall health profile.
How can I find out if I have this variant?
This variant may be included in some direct-to-consumer genetic tests or clinical genomic panels. You should check the specific documentation provided by your testing service to see if this SNP is included in their report.
What should I do if I am concerned about my breast cancer risk?
If you are concerned about your risk, you should speak with a healthcare provider or a genetic counselor. They can evaluate your family history and personal health factors to determine if further screening or genetic testing is appropriate for you.
Is rs4784227 the only genetic factor for breast cancer?
No, breast cancer risk is highly complex and involves hundreds of genetic variants, as well as environmental and lifestyle factors. This SNP is just one small piece of a much larger genetic puzzle.
Sources & further reading
Educational information only, last refreshed 9/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4784227?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in TOX3
This locus variant in TOX3 confers a moderately increased risk of estrogen receptor-positive breast cancer.
Intronic susceptibility locus strongly associated with altered TOX3 enhancer activity and increased risk of estrogen receptor-positive breast cancer.
A common intergenic risk allele at the 16q12/TOX3 locus strongly associated with estrogen receptor-positive breast cancer susceptibility.